AUGMENTATION AND RISK FACTORS WITH LONG-TERM FOLLOW UP IN JAPANESE PATIENTS WITH RESTLESS LEGS SYNDROME

被引：0
|
作者：
Tanioka, K. [1 ,2 ,3 ]
Okura, M. [4 ]
Inoue, M. [4 ]
Taniguchi, K. [3 ]
Taniguchi, M. [4 ]
Hamano, T. [5 ]
Tachibana, N. [3 ,6 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Neurol, Kyoto, Japan
[2] Kyoto Univ, Fac Med, Kyoto, Japan
[3] Kansai Elect Power Hosp, Dept Neurol, Ctr Sleep Related Disorders, Osaka, Japan
[4] Osaka Kaisei Hosp, Sleep Med Ctr, Osaka, Japan
[5] Kansai Elect Power Hosp, Dept Neurol, Osaka, Japan
[6] Kansai Elect Power Med Res Inst, Div Sleep Med, Osaka, Japan
来源：
SLEEP MEDICINE | 2017年 / 40卷
关键词：
D O I：
10.1016/j.sleep.2017.11.954
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E325 / E325
页数：1
相关论文
共 50 条
  • [31] Long-term course of restless legs syndrome in dialysis patients after kidney transplantation
    Winkelmann, J
    Stautner, A
    Samtleben, W
    Trenkwalder, C
    MOVEMENT DISORDERS, 2002, 17 (05) : 1072 - 1076
  • [32] LONG-TERM EFFECT OF DOPAMINERGIC DRUGS IN RESTLESS LEGS - A 2-YEAR FOLLOW-UP
    VONSCHEELE, C
    KEMPI, V
    ARCHIVES OF NEUROLOGY, 1990, 47 (11) : 1223 - 1224
  • [33] Prevalence and Risk Factors of Restless Legs Syndrome in Hemodialysis Patients
    Zhang, Li-Yan
    Ma, Xiao-Yang
    Lin, Jun
    Liu, Wen-Hu
    Guo, Wang
    Yin, Le
    Wang, Shi-Xiang
    Li, Xia
    Li, Jing
    Jin, Li-Li
    Tian, Ze-Long
    Du, Yi-Tong
    Tuo, Hou-Zhen
    NATURE AND SCIENCE OF SLEEP, 2020, 12 : 19 - 27
  • [34] Changes in neuroendocrine response to L-DOPA during long-term treatment in restless legs syndrome augmentation
    Garcia-Borreguero, D
    Egatz, R
    Larrosa, O
    Serrano, C
    MOVEMENT DISORDERS, 2004, 19 : S396 - S397
  • [35] Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation
    Mackie, Susan
    Winkelman, John W.
    CNS DRUGS, 2015, 29 (05) : 351 - 357
  • [36] Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation
    Susan Mackie
    John W. Winkelman
    CNS Drugs, 2015, 29 : 351 - 357
  • [37] Cardiovascular Risk Factors in Restless Legs Syndrome
    Schlesinger, Ilana
    Erikh, Ilana
    Avizohar, Ophir
    Sprecher, Elliot
    Yarnitsky, David
    MOVEMENT DISORDERS, 2009, 24 (11) : 1587 - 1592
  • [38] The risk factors of restless legs syndrome (RLS)
    Smiljkovic, T.
    Kostic, S.
    Potic, J.
    Martinovic, J.
    Potic, B.
    Malovic, J.
    Radlovic, A.
    Palibrk, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 111 - 111
  • [39] Cardiovascular risk factors in restless legs syndrome
    Schlesinger, I.
    Erikh, I.
    Avizohar, O.
    Sprecher, E.
    Yarnitsky, D.
    MOVEMENT DISORDERS, 2008, 23 (01) : S363 - S363
  • [40] A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis
    Tanaka, K
    Sakai, H
    Hashizume, M
    Hirohata, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (12): : 1241 - 1250
12345